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Human papillomavirus has emerged as the leading infectious cause of cervical and other anogenital cancers. We have studied
the relation between human papillomavirus infection and the subsequent risk of anal and perianal skin cancer. A case–cohort
study within two large Nordic serum banks to which about 760000 individuals had donated serum samples was performed.
Subjects who developed anal and perianal skin cancer during follow up (median time of 10 years) were identiﬁed by registry
linkage with the nationwide cancer registries in Finland and Norway. Twenty-eight cases and 1500 controls were analysed for
the presence of IgG antibodies to HPV 16, 18, 33 or 73, and odds ratios of developing anal and perianal skin cancer were
calculated. There was an increased risk of developing anal and perianal skin cancer among subjects seropositive for HPV 16
(OR=3.0; 95%CI=1.1–8.2) and HPV 18 (OR=4.4; 95%CI=1.1–17). The highest risks were seen for HPV 16 seropositive
patients above the age of 45 years at serum sampling and for patients with a lag time of less than 10 years. This study
provides prospective epidemiological evidence of an association between infection with HPV 16 and 18 and anal and perianal
skin cancer.
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Anal epidermoid carcinoma is a rare tumour, but its incidence has
increased over the past 30 years (Goldman et al, 1989; Frisch et al,
1993; Melbye et al, 1994). Sexual behaviour and smoking are risk
factors (Daling et al, 1992; Frisch et al, 1997). A high proportion
of anal tumours are associated with human papillomavirus
(HPV) infection (Melbye and Frisch, 1998). HPV 16 DNA has been
reported in up to 93% of invasive squamous anal tumours and
69% of anal carcinoma in situ (Tilston, 1997).
Most epidemiological studies on HPV infection and anal cancer
have been case–series and case–control studies using samples
taken after the cancer has been diagnosed. Such studies may be
subject to differential misclassiﬁcation related to the presence of
the disease, and provide no information on the temporal order
of events. Prospective studies are generally considered crucial for
causality inference. As primary prevention of HPV infection by
vaccination is being evaluated, it is important to establish which
cancers are likely to be amenable to prevention. Prospective sero-
epidemiological studies have linked HPV to vulvar, vaginal and
to a subset of head and neck cancers (Bjørge et al, 1997a; Mork
et al, 2001).
HPV serology, using capsids of HPV 16, 18 and 33, has been
validated as a type-restricted marker of past or present HPV infec-
tion (Dillner, 1999). A serologic association of HPV 16 with
incident anal cancer has been shown (Heino et al, 1995). In a study
of the role of HPV in non-cervical anogenital cancers, we found
that HPV 16 seropositivity conferred an increased risk for non-
cervical anogenital cancers, but not for anal cancer (Bjørge et al,
1997a). This was in spite of the fact that the proportion of anal
cancer cases (25%) being HPV 16 seropositive was higher than
for other non-cervical anogenital cancers (24%). This difference
could not be explained by the matching criteria, suggesting that
random variability among the controls (n=59) might be an expla-
nation.
To investigate if the negative results did imply that the associa-
tion is not causal or whether it might be explained by insufﬁcient
study size, we expanded our previous study to include a larger
number of controls. Further, we used a later updated linkage of
our data sources for an evaluation of the risk of developing anal
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www.bjcancer.comfrom 460000 pregnant women. By 1996 almost one million blood
specimens had been stored. The samples are collected at maternity
clinics from almost all (about 98%) pregnant women in Finland
during early pregnancy (ﬁrst trimester) to screen for congenital
infections. The samples are stored at 7208C.
The Janus project was started in 1973 and contains about
600000 serum samples from about 300000 donors. The samples
have been collected from people who participated in county health
examinations, mostly for cardiovascular diseases, and from blood
donors. The participants in the health examinations were recruited
from several counties in Norway. The blood donors were from the
Red Cross Blood Donor Centre in Oslo. The samples are stored at
7258C.
Cancer registries
Both the Finnish and the Norwegian cancer registries are nation-
wide and population based. Since 1953 they have received
notiﬁcations from hospitals, pathology and haematology labora-
tories, and physicians. They provide information about site,
histological type, and stage of disease at the time of diagnosis.
The registration of solid cancers is regarded as practically complete
(Lund, 1981; Teppo et al, 1994). Registration was based on a modi-
ﬁed version of International Classiﬁcation of Diseases, 7th revision.
Identiﬁcation of cases and controls
The data ﬁles of the serum banks and cancer registries were linked
on the basis of the personal identiﬁcation number to identify anal
(ICD-7 code 154.1), perianal skin (ICD-7 code 191.4) and head
and neck cancers (ICD-7 codes 140–148 and 160–161). If there
were several serum samples available for each case, the ﬁrst sample
was chosen. Five (Norway) or seven (Finland) controls were
selected from the cohorts for each case. The controls were indivi-
dually matched for cohort, sex, age at serum sampling (within 2
years), storage time (within 2 months), country and, in Norway,
for county of residence. Neither cases nor controls had any cancer
diagnoses prior to the present cancer diagnoses.
In Norway, 23 anal and perianal skin cancer cases (13 women
and 10 men) were identiﬁed. Altogether 20 cases were anal cancer
and three were perianal skin cancer. Fifteen of the anal cancer cases
were squamous cell carcinoma, three were cloacogenic carcinoma,
one was adenocarcinoma and one was transitional cell carcinoma.
The three perianal skin cancers were all squamous cell carcinoma.
In Finland, ﬁve cases (all anal cancer) were identiﬁed. Three cases
were squamous cell carcinoma and two were adenocarcinoma. No
in situ cases were included. Serum samples from 1500 controls were
available for analysis.
In the present study, all controls were used for analysis using a
case–cohort study design. The sampling with matching criteria
thus only served to increase statistical power by frequency match-
ing controls to the major cancer sites in the study. The results of
the head and neck cancer analyses are published separately (Mork
et al, 2001).
The median age at diagnosis was 57 years (range 43–68 years)
for the Norwegian and 39 years (range 32–44 years) for the
Finnish cases. Median time between withdrawal of serum and diag-
nosis was 10 years (range 1.9–22 years) and 8.3 years (range 6.0–
12 years) for the Norwegian and Finnish cases, respectively.
Compared with our previous study (Bjørge et al, 1997a), three
more anal cancer cases were identiﬁed in Norway and four in
Finland. However, in Norway two of the previous anal cancer cases
were excluded due to multiple malignancies. Further, two of the
previous perianal skin cancer cases were also excluded, one due
to multiple malignancies, the other due to histology (Paget’s
disease of perineum). These exclusions were decided at the outset
of this study and without knowledge of the serological results of
the previous study (Bjørge et al, 1997a).
Laboratory methods
Seropositivity to HPV capsids was determined by an established
and validated enzyme linked immunosorbent assay (ELISA) using
baculovirus expressed capsids comprising both the L1 and L2
proteins, with disrupted capsids of bovine papillomavirus as
control (Heino et al, 1995). The cut-off levels used to assign sero-
positivity were preassigned and, relative to internal standards,
identical to the cut-offs used in previous studies (HPV 16: cut-
off level 354, HPV 18, 33 and 73: cut-off level 100) (Bjørge et al,
1997a,b; Dillner et al, 1997).
All laboratory analyses were performed on masked samples.
Statistical analyses
The data was analysed in a case–cohort design. Odds ratios (ORs)
and their 95% conﬁdence intervals (95%CI) were derived from
Cox proportional hazard regression models (Cox and Oakes,
1984), using the program package Epicure (Preston et al, 1993;
Hirosoft International Corporation, 2000). In the analyses, the
‘risk-time’ for each person, i.e. the time from serum sampling until
the election date, was used as the time variable. Sex (two cate-
gories), age (three categories), time of serum sampling (four
categories) and serumbank/area of residence (ﬁve categories;
Finland, Oslo county, Finnmark county, other Norwegian counties
and Red Cross blood donors) were adjusted for.
RESULTS
Overall, 50% (14 patients) of the anal and perianal skin cancer
cases was seropositive for HPV 16, 18, 33 or 73. Eight cases were
seropositive for HPV 16, ﬁve for HPV 18, six for HPV 33 and
one case was seropositive for HPV 73. There was an increased risk
of developing anal and perianal skin cancer among subjects sero-
positive for HPV 16 (OR=3.0; 95%CI=1.1–8.2) and HPV 18
(OR=4.4; 95%CI=1.1–17), with adjustment for the other serotypes
(Table 1). In the Norwegian part of the study, ORs were also calcu-
lated dichotomising on age and lag time until cancer diagnosis.
Higher odds ratios for anal cancer were observed among HPV 16
seropositive subjects above 45 years of age (OR=7.3;
95%CI=1.5–37) and with less than 10 years lag (OR=6.2;
95%CI=1.4–26), with adjustment for the other serotypes. Lower
odds ratios were seen for the other serotypes. No substantial differ-
ences in odds ratios were found when the analyses were restricted
to anal cancer, to squamous cell carcinoma or to women, respec-
tively (data not shown).
DISCUSSION
The present study has provided prospective epidemiological
evidence that infection with HPV 16 and 18 does confer an
increased risk for future anal and perianal skin cancer. The highest
risks were seen for HPV 16 seropositive patients above the age of
45 years at serum sampling and for patients with a lag time of less
than 10 years.
The role of a sexually transmitted agent in the etiology of anal
cancer was ﬁrst suggested in 1979 (Cooper et al, 1979). Similar to
the cervix, the anal canal has a squamocolumnar junction or trans-
formation zone, which appears to be particularly susceptible to HPV
infection, and the concomitant risk of intraepithelial neoplasia and
carcinoma (Tilston, 1997). It is now well established that HPV play a
central role in the pathogenesis of anogenital cancers and their
precursors (International Agency for Research on Cancer, 1995;
Ryan et al, 2000). HPV DNA has been detected in invasive as well
as in anal squamous intraepithelial lesions. HPV 16 is the most
common type found. In situ hybridisation studies have found 24–
73% of cases to be HPV DNA positive, whereas the corresponding
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1995). HPV DNA is almost always found integrated into the host
chromosome, but it is frequently coexistent with episomal DNA
in the cell nucleus (Holm et al, 1994; Tilston, 1997).
However, the detection of HPV DNA implies current infection
only. Prior exposure is not necessarily reﬂected. By applying HPV
serology, a marker of both past and present HPV infection, it has
been possible to investigate possible temporal associations of HPV
infection with anal cancer. Previously, a serologic association of
HPV 16 with incident anal cancer has been reported (Heino et al,
1995). In our previous, prospective study, no association of HPV
and anal cancer was found, although a high, but insigniﬁcant risk
was found for perianal skin cancer (Bjørge et al, 1997a). The present
expanded study is, to our knowledge, the ﬁrst study providing
prospective epidemiologic evidence of an association between
HPV infection and anal and perianal skin cancer. Subjects seroposi-
tive for HPV 16 and also for HPV 18 were at an increased risk.
Patients with HPV DNA in their anal tumours have been
reported to be about 10 years younger than those with HPV
DNA-negative anal cancers (Heino et al, 1993). In this study, the
mean age of the cases being seropositive for any HPV was 54 years,
whereas the mean age of the seronegative cases was 53 years.
At present, the incidence of anal cancer is about two to three
times higher in women than in men. Particularly in women, the
incidence has increased substantially over the past decades. A high-
er proportion of anal cancer cases has been reported to be positive
for HPV DNA in women compared to men (Holm et al, 1994;
Frisch et al, 1997). In the present study, 28% of the female and
30% of the male cases were seropositive for HPV 16. Similar
ﬁgures for HPV 18 were 17% and 20%, respectively.
In summary, this study provides prospective epidemiological
evidence indicating that infection with HPV 16 and also HPV 18
does increase the risk for subsequent development of anal and peri-
anal skin cancer.
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Table 1 Risk of developing anal and perianal skin cancer (n=28) according to the presence of IgG antibodies to different
human papillomavirus (HPV) types; case–cohort design*
% Positive Without adjustment for the
other HPV types
With adjustment for the
other HPV types
HPV type Cases (n=28) Controls (n=1500) OR (95% CI) OR (95% CI)
HPV 16
a 29 8 3.0 (1.1–7.6) 3.0 (1.1–8.2)
HPV 18
b 18 7 3.4 (1.0–11) 4.4 (1.1–17)
HPV 33
b 21 11 1.5 (0.5–4.6) 1.0 (0.2–4.0)
HPV 16, 18 or 33 50 19 3.7 (1.6–8.8) 4.2 (1.8–10)
HPV 73
b 4 7 0.5 (0.1–4.1) 0.2 (0.0–1.8)
aHPV 16: cut-off level, 354.
bHPV 18, 33 and 73: cut-off level, 100. *Sex (two categories), age (three categories), time of serum sampling
(four categories) and serumbank/area of residence (ﬁve categories; Finland, Oslo county, Finnmark county, other Norwegian counties and
Red Cross blood donors) were adjusted for in all models.
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